Actinium Pharmaceuticals, Inc. (ATNM) — Analyst outlook / Analyst consensus target is. Based on 11 analyst ratings, the consensus is bullish — 11 Buy.
The consensus price target is $11.07 (low: $4.00, high: $24.26), representing an upside of 906.4% from the current price $1.10.
Analysts estimate Earnings Per Share (EPS) of $-1.41 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.27 vs est $-1.41 (beat +10.2%). 2025: actual $-1.09 vs est $-1.08 (missed -1.4%). Analyst accuracy: 94%.
ATNM Stock — 12-Month Price Forecast
$11.07
▲ +906.36% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Actinium Pharmaceuticals, Inc., the average price target is $11.07, with a high forecast of $24.26, and a low forecast of $4.00.
The average price target represents a +906.36% change from the last price of $1.10.
Highest Price Target
$24.26
Average Price Target
$11.07
Lowest Price Target
$4.00
ATNM Analyst Ratings
Buy
Based on 11 analysts giving stock ratings to Actinium Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — ATNM
94%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.27
vs Est –$1.41
▲ 11.3% off
2025
Actual –$1.09
vs Est –$1.08
▼ 1.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ATNM
100%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2025
Actual $0.000B
vs Est $0.000B
▼ 0.0% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
